ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

New Treatment For Malignant Glioma, IL13-PE38, Tested In Early Clinical Trials

December 28, 2001

In Brief: City of Hope launches Hematologic Malignancies and Stem Cell Transplantation Institute

October 31, 2014

Brigid Levental, Pediatric researcher, Dead At 58

February 18, 1994

Reviewers Report Progress In New Drug Prescreen System Development, Commend DTP

December 15, 1989

“Dog And Pony Show” At FCRF For NCAB OFF

April 25, 1980

Four New DCCP Abs Established Without New Slots, More Money

January 15, 1982